TY  - JOUR
AU  - Vidović, Marija
AU  - Rikalović, Milena G.
PY  - 2022
UR  - https://imagine.imgge.bg.ac.rs/handle/123456789/1598
AB  - Following Alzheimer's, Parkinson's disease (PD) is the second-most common neurodegenerative disorder, sharing an unclear pathophysiology, a multifactorial profile, and massive social costs worldwide. Despite this, no disease-modifying therapy is available. PD is tightly associated with alpha-synuclein (alpha-Syn) deposits, which become organised into insoluble, amyloid fibrils. As a typical intrinsically disordered protein, alpha-Syn adopts a monomeric, random coil conformation in an aqueous solution, while its interaction with lipid membranes drives the transition of the molecule part into an alpha-helical structure. The central unstructured region of alpha-Syn is involved in fibril formation by converting to well-defined, beta-sheet rich secondary structures. Presently, most therapeutic strategies against PD are focused on designing small molecules, peptides, and peptidomimetics that can directly target alpha-Syn and its aggregation pathway. Other approaches include gene silencing, cell transplantation, stimulation of intracellular clearance with autophagy promoters, and degradation pathways based on immunotherapy of amyloid fibrils. In the present review, we summarise the current advances related to alpha-Syn aggregation/neurotoxicity. These findings present a valuable arsenal for the further development of efficient, nontoxic, and non-invasive therapeutic protocols for disease-modifying therapy that tackles disease onset and progression in the future.
PB  - MDPI, Basel
T2  - Cells
T1  - Alpha-Synuclein Aggregation Pathway in Parkinson's Disease: Current Status and Novel Therapeutic Approaches
IS  - 11
VL  - 11
DO  - 10.3390/cells11111732
ER  - 

@article{
author = "Vidović, Marija and Rikalović, Milena G.",
year = "2022",
abstract = "Following Alzheimer's, Parkinson's disease (PD) is the second-most common neurodegenerative disorder, sharing an unclear pathophysiology, a multifactorial profile, and massive social costs worldwide. Despite this, no disease-modifying therapy is available. PD is tightly associated with alpha-synuclein (alpha-Syn) deposits, which become organised into insoluble, amyloid fibrils. As a typical intrinsically disordered protein, alpha-Syn adopts a monomeric, random coil conformation in an aqueous solution, while its interaction with lipid membranes drives the transition of the molecule part into an alpha-helical structure. The central unstructured region of alpha-Syn is involved in fibril formation by converting to well-defined, beta-sheet rich secondary structures. Presently, most therapeutic strategies against PD are focused on designing small molecules, peptides, and peptidomimetics that can directly target alpha-Syn and its aggregation pathway. Other approaches include gene silencing, cell transplantation, stimulation of intracellular clearance with autophagy promoters, and degradation pathways based on immunotherapy of amyloid fibrils. In the present review, we summarise the current advances related to alpha-Syn aggregation/neurotoxicity. These findings present a valuable arsenal for the further development of efficient, nontoxic, and non-invasive therapeutic protocols for disease-modifying therapy that tackles disease onset and progression in the future.",
publisher = "MDPI, Basel",
journal = "Cells",
title = "Alpha-Synuclein Aggregation Pathway in Parkinson's Disease: Current Status and Novel Therapeutic Approaches",
number = "11",
volume = "11",
doi = "10.3390/cells11111732"
}

Vidović, M.,& Rikalović, M. G.. (2022). Alpha-Synuclein Aggregation Pathway in Parkinson's Disease: Current Status and Novel Therapeutic Approaches. in Cells
MDPI, Basel., 11(11).
https://doi.org/10.3390/cells11111732

Vidović M, Rikalović MG. Alpha-Synuclein Aggregation Pathway in Parkinson's Disease: Current Status and Novel Therapeutic Approaches. in Cells. 2022;11(11).
doi:10.3390/cells11111732 .

Vidović, Marija, Rikalović, Milena G., "Alpha-Synuclein Aggregation Pathway in Parkinson's Disease: Current Status and Novel Therapeutic Approaches" in Cells, 11, no. 11 (2022),
https://doi.org/10.3390/cells11111732 . .